长效 HIV 治疗与预防：更接近目标。
Long-Acting HIV Treatment and Prevention: Closer to the Threshold.
机构信息
Associate Editor, Global Health: Science and Practice, and Medical Officer, U.S. Agency for International Development, Washington, DC, USA.
出版信息
Glob Health Sci Pract. 2017 Jun 27;5(2):182-187. doi: 10.9745/GHSP-D-17-00206.
Abstract
Substantial progress has been made toward viable, practical long-acting approaches to deliver HIV treatment and prevention through: (1) continued improvements in long-acting antiretrovirals (ARVs); (2) better innovative delivery systems; and (3) collaboration of willing partners to advance new ARVs. More progress on those 3 fronts is still needed to arrive at the goal of optimized HIV treatment and prevention for all who would benefit—and of finally controlling the HIV epidemic.
摘要
在以下方面已经取得了重大进展，为通过：（1）长效抗逆转录病毒药物的持续改进；（2）更好的创新给药系统；（3）愿意合作的合作伙伴共同推进新的抗逆转录病毒药物，实现长效、可行、实用的 HIV 治疗和预防方法：需要在这 3 个方面取得更多进展，才能实现为所有受益人群优化 HIV 治疗和预防的目标——最终控制艾滋病毒流行。
相似文献
1
Long-Acting HIV Treatment and Prevention: Closer to the Threshold.长效 HIV 治疗与预防：更接近目标。
Glob Health Sci Pract. 2017 Jun 27;5(2):182-187. doi: 10.9745/GHSP-D-17-00206.
2
Long-acting injectable for HIV approved for use in the UK.长效注射用抗艾滋病毒药物在英国获批使用。
Lancet Infect Dis. 2022 Jan;22(1):26. doi: 10.1016/S1473-3099(21)00775-1.
3
Long-acting HIV drugs advanced to overcome adherence challenge.长效抗艾滋病毒药物取得进展以克服依从性挑战。
Nat Med. 2014 Apr;20(4):323-4. doi: 10.1038/nm0414-323.
4
Long-Acting HIV Drugs for Treatment and Prevention.长效抗 HIV 药物：治疗与预防用途
Annu Rev Med. 2019 Jan 27;70:137-150. doi: 10.1146/annurev-med-041217-013717. Epub 2018 Oct 24.
5
Long-acting agents for HIV infection: biological aspects, role in treatment and prevention, and patient's perspective.用于治疗HIV感染的长效药物：生物学特性、在治疗和预防中的作用以及患者视角
New Microbiol. 2017 Apr;40(2):75-79. Epub 2017 Apr 3.
6
Long-acting drugs and formulations for the treatment and prevention of HIV infection.长效药物和制剂，用于治疗和预防 HIV 感染。
Int J Antimicrob Agents. 2021 Jan;57(1):106220. doi: 10.1016/j.ijantimicag.2020.106220. Epub 2020 Nov 6.
7
Long-acting injectable antiretrovirals for HIV treatment and prevention.长效注射型抗逆转录病毒药物治疗和预防艾滋病。
Curr Opin HIV AIDS. 2013 Nov;8(6):565-71. doi: 10.1097/COH.0000000000000002.
8
Extending access with long-acting antiretroviral therapy: the next advance in HIV-1 therapeutics and prevention.通过长效抗逆转录病毒疗法扩大可及性：HIV-1治疗与预防的下一个进展。
Curr Opin HIV AIDS. 2015 Jul;10(4):216-8. doi: 10.1097/COH.0000000000000167.
9
[New reality in HIV therapy: Long-acting, injectable drugs].[艾滋病治疗的新现实：长效注射药物]
MMW Fortschr Med. 2022 Jun;164(Suppl 2):44-51. doi: 10.1007/s15006-022-1020-y.
10
Is Long-Acting Injectable Cabotegravir Likely to Expand PrEP Coverage Among MSM in the District of Columbia?长效注射用卡博特韦有可能扩大哥伦比亚特区男男性行为者的暴露前预防覆盖范围吗？
J Acquir Immune Defic Syndr. 2021 Mar 1;86(3):e80-e82. doi: 10.1097/QAI.0000000000002557.
引用本文的文献
1
Examining the Role of Posttraumatic Stress and Depressive Symptoms in HIV Pre-exposure Prophylaxis (PrEP) Motivation Among Women Survivors of Intimate Partner Violence.探讨创伤后应激和抑郁症状在亲密伴侣暴力女性幸存者的HIV暴露前预防（PrEP）动机中的作用。
AIDS Behav. 2025 Feb;29(2):453-467. doi: 10.1007/s10461-024-04531-8. Epub 2024 Nov 25.
2
Glyoxal Caging of Nucleoside Antivirals toward Self-Activating, Extended-Release Prodrugs.糖醛基笼化核苷类抗病毒药物，以实现自我激活、延长释放前药。
J Am Chem Soc. 2024 Oct 30;146(43):29402-29406. doi: 10.1021/jacs.4c08371. Epub 2024 Oct 16.
3
Novel Perspectives on the Design and Development of a Long-Acting Subcutaneous Raltegravir Injection for Treatment of HIV-In Vitro and In Vivo Evaluation.用于治疗HIV的长效皮下注射拉替拉韦设计与开发的新视角——体外和体内评价
Pharmaceutics. 2023 May 18;15(5):1530. doi: 10.3390/pharmaceutics15051530.
4
Long-acting antiretrovirals: a new era for the management and prevention of HIV infection.长效抗逆转录病毒药物：HIV 感染管理和预防的新时代。
J Antimicrob Chemother. 2022 Feb 2;77(2):290-302. doi: 10.1093/jac/dkab324.
5
Biodegradable polymeric solid implants for ultra-long-acting delivery of single or multiple antiretroviral drugs.可生物降解聚合物固体植入物，用于长效单一或多种抗逆转录病毒药物的递送。
Int J Pharm. 2021 Aug 10;605:120844. doi: 10.1016/j.ijpharm.2021.120844. Epub 2021 Jul 1.
6
Use of propensity score matching to create counterfactual group to assess potential HIV prevention interventions.使用倾向评分匹配创建反事实组，以评估潜在的 HIV 预防干预措施。
Sci Rep. 2021 Mar 29;11(1):7017. doi: 10.1038/s41598-021-86539-x.
7
Why Counseling Intervention Fails to Improve Compliance towards Antiretroviral Therapy: Findings from a Mixed-Methods Study among People Living with HIV in Bali Province, Indonesia.为何咨询干预未能提高抗逆转录病毒治疗的依从性：印度尼西亚巴厘省HIV感染者的一项混合方法研究结果
Infect Dis Rep. 2021 Feb 5;13(1):136-147. doi: 10.3390/idr13010015.
8
Pharmaceutical Approaches to HIV Treatment and Prevention.艾滋病病毒治疗与预防的药物方法
Adv Ther (Weinh). 2018 Oct;1(6). doi: 10.1002/adtp.201800054. Epub 2018 Jul 29.
9
Comparison of HIV Risk Behaviors Between Clinical Trials and Observational Cohorts in Uganda.乌干达临床试验与观察队列中 HIV 风险行为的比较。
AIDS Behav. 2020 Oct;24(10):2872-2884. doi: 10.1007/s10461-020-02838-w.
10
The only way is up: priorities for implementing long-acting antiretrovirals for HIV prevention and treatment.唯一的出路：长效抗逆转录病毒在艾滋病预防和治疗中的实施重点。
Curr Opin HIV AIDS. 2020 Jan;15(1):73-80. doi: 10.1097/COH.0000000000000601.
本文引用的文献
1
A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings.一项评估 VRC01 广谱中和单克隆抗体在撒哈拉以南非洲地区女性中降低 HIV-1 感染发生率的安全性和有效性的 2b 期研究：基线结果。
J Acquir Immune Defic Syndr. 2021 May 1;87(1):680-687. doi: 10.1097/QAI.0000000000002649.
2
Accelerating access and scale-up of optimized ART in low-income and middle-income countries: a call for a coordinated end-to-end approach.加快低收入和中等收入国家优化抗逆转录病毒治疗的可及性并扩大其规模：呼吁采取协调一致的端到端方法。
Curr Opin HIV AIDS. 2017 Jul;12(4):383-389. doi: 10.1097/COH.0000000000000383.
3
Use of broadly neutralizing antibodies for HIV-1 prevention.使用广泛中和抗体预防HIV-1感染。
Immunol Rev. 2017 Jan;275(1):296-312. doi: 10.1111/imr.12511.
4
Expanding Access to a New, More Affordable Levonorgestrel Intrauterine System in Kenya: Service Delivery Costs Compared With Other Contraceptive Methods and Perspectives of Key Opinion Leaders.肯尼亚扩大新型、更实惠左炔诺孕酮宫内节育系统的使用：服务提供成本与其他避孕方法的比较以及主要意见领袖的观点。
Glob Health Sci Pract. 2016 Aug 18;4 Suppl 2(Suppl 2):S83-93. doi: 10.9745/GHSP-D-15-00327. Print 2016 Aug 11.
5
Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.用于预防和治疗HIV-1 C亚型感染的广谱中和抗体的最佳组合
PLoS Pathog. 2016 Mar 30;12(3):e1005520. doi: 10.1371/journal.ppat.1005520. eCollection 2016 Mar.
6
A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis.一种可调节、可生物降解的薄膜聚合物装置，作为长效植入剂用于递送富马酸替诺福韦艾拉酚胺以进行HIV暴露前预防。
Pharm Res. 2016 Jul;33(7):1649-56. doi: 10.1007/s11095-016-1904-6. Epub 2016 Mar 14.
7
Microneedles: A New Frontier in Nanomedicine Delivery.微针：纳米医学给药的新前沿。
Pharm Res. 2016 May;33(5):1055-73. doi: 10.1007/s11095-016-1885-5. Epub 2016 Feb 23.
8
Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.替诺福韦艾拉酚胺：一种用于治疗人类免疫缺陷病毒的新型替诺福韦前药。
Antiviral Res. 2016 Jan;125:63-70. doi: 10.1016/j.antiviral.2015.11.009. Epub 2015 Nov 27.
9
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.暴露前预防以预防HIV-1感染（PROUD）：一项实用开放标签随机试验试点阶段的有效性结果
Lancet. 2016 Jan 2;387(10013):53-60. doi: 10.1016/S0140-6736(15)00056-2. Epub 2015 Sep 9.
10
In vivo release of levonorgestrel from Sino-implant (II) — an innovative comparison of explant data.左炔诺孕酮从皮下埋植剂（II型）的体内释放——外植体数据的创新性比较
Contraception. 2015 Oct;92(4):350-5. doi: 10.1016/j.contraception.2015.06.028. Epub 2015 Jul 2.
Zotero 插件